U.S. markets closed

Xenetic Biosciences, Inc. (XBIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.8600+0.0200 (+1.09%)
At close: 4:00PM EDT
Sign in to post a message.
  • M
    Mike
    This is going to $30 a share
  • T
    Tom
    when will they have to issue more shares to pay the expenses and salarys
  • J
    James
    The company has received approval to commence its exploratory patient biopsy trial in Europe to evaluate XCART, a personalised CAR-T platform technology engineered to target patient- and tumour-specific antigens.
  • a
    alen
    I love what this company is doing and I am long but it hurts seeing the stock drop like this..
  • R
    Russian Bear
    Xenetic Biosciences, Inc. Announces Research and Development Collaboration with Scripps Research to Advance XCART(TM) Platform :: Xenetic Biosciences, Inc. (XBIO)
    www.xeneticbio.com
    Bullish
  • z
    zig
    lets wait for another offering...
  • T
    Tom
    thats good news to comence exploratory study of xcart.now they can issue more shares.and pay for it.and get nowhere for another year
  • J
    JJ
    3K shares in the first 1/2 hour. That’s my Friday night bar tab.
    Neutral
  • N
    None Yo Biz
    If this hit $3.50 before the next offering it'll be a miracle....oh, and I'll close my position.
  • T
    Tom
    they never have news do they.oh well.maybe next year
  • T
    Tom
    Nothing at all going on with them.same as last quarter
  • T
    Tom
    1 year chart.97 cents.they WILL issue more shares soon
  • T
    Tom
    the earnings wont be good.they have no funds.and need to issue shares.it will go to 1.70 again
  • M
    Max V
    Good volume growth. Good press releases and upcoming conferences. Regarding the hemoglobinopathies that come along with covid19 + RU finally obtaining a erythropoietin for dialysis patients. I see good health. 🚀🚀
  • J
    JJ
    There is no reason for this stock to go down with this news. Earnings in 45 days and now partnerships developing.
    Bullish
  • T
    Tom
    glad I sold
  • l
    lacali
    Xenetic Biosciences, Inc.’s partner, PJSC Pharmsynthez, reports to had positive data from its pivotal Phase 3 clinical study leveraging PolyXen® to create a treatment for anemia in patients with chronic kidney disease. Check the disclaimer on the landing page. Moreover, are curious with these other companies that could probably treat Relapsed or Refractory Acute Myeloid Leukemia with a promising drug candidate? If yes, have fun reading and relieve that curiosity here: http://b.link/PotentialUnmetMedicalNeedTreatment
    Potential New Treatment For Unmet Medical Need Turns Investors Necks
    Potential New Treatment For Unmet Medical Need Turns Investors Necks
    b.link
    Bullish
  • l
    lau
    When it will increase back to 5?
    Bullish
  • T
    Trading_amie
    Looks like it might be time to check out another biotech that I have been watching. I have no idea why this is down so much in the premarket. Anyone know? https://emergingstocks.market/9bjxa
    PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced it has entered into a ne
    PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced it has entered into a ne
    emergingstocks.market